Tocilizumab and adalimumab in an 18q deletion syndrome patient with chronic arthritis

Sirs,
A case of 18q deletion syndrome (18q-syndrome) was reported in 1964 by De Grouchy et al.; the syndrome exhibits diverse symptoms such as mental retardation, short stature, and poor muscle tone (1). Some studies have reported an association between chromosome 18 and immunocompetence. For example, the haplo-insufficiency of the 18q22.3-q23 gene region may be associated with the immunoglobulin A deficiency phenotype (2), and chromosome 18 may contain a locus that is responsible for the regulation of both Th1 and Th2 cytokine production (3). Here we report the case of a patient with 18q-syndrome and an autoimmune disease of chronic arthritis.

A 10-month-old girl who was unable to crawl underwent a genetic screening that revealed the presence of 18q-syndrome [46, xx, del (18)(q22-qter)]. She had delayed mental development, whereas no malformation and abnormality were observed in motor development. The girl developed nephrotic syndrome (NS) at the age of 1 year; her kidney function had a waxing and waning course until 7 years of age. The immunosuppressive drugs for the NS included methylprednisolone, mizoribine, and cyclosporine. After a successful course of treatment, the mizoribine and cyclosporine were discontinued at the age of 11 years and 7 months. One month later, she complained of general malaise, a loss of appetite, and joint pain, and she was then referred to the pediatric department in our hospital. Biochemical examination of her blood showed the following results: white blood cells, 8,990/μL; haemoglobin, 14.8 g/dL; platelets, 35.5 × 10^9/μL; erythrocyte sedimentation rate, 123 mm/h; C-reactive protein, 2.81 mg/dL; rheumatoid factor, 469.8 IU/mL; 50% haemolytic unit of complement, 61.9 U/mL; ferritin, 114 ng/mL; anti-nuclear antibody, <80 times the normal; matrix metalloproteinase-3 (MMP-3), 195 ng/mL; anti-cyclic citrullinated peptide antibody, 293 U/mL; immunoglobulin G, 830 mg/dL; immunoglobulin A, 188 mg/dL; immunoglobulin M, 411 mg/dL; immunoglobulin D, 10.7 mg/dL; interleukin-6, 113 pg/mL; soluble interleukin-2 receptor, 812 U/mL; and tumour necrosis factor-α, 1.4 pg/mL. The prototypes of the HLA allele were HLA-A*24:31, B*71:51, and DB1*04:14. She complained of pain in her neck, both hands, and her wrists. Magnetic resonance imaging (MRI) revealed irregular patterns of the dens, bilateral carpals, and the distal radius as well as synovial inflammation with fibrosis that contributed to the low signal intensity on the T1-weighted images and the high signal intensity on the T2-weighted images. Accordingly, the patient was diagnosed with inflammatory arthropathies. She was treated with methotrexate 5 mg/m^2/week (Japanese initial dose), ibuprofen 10 mg/kg/day, and prednisolone 2 mg/kg/day; however, MRI showed more extensive synovial inflammation in the radius after 2 months because the methotrexate dose was extremely insufficient to manage her inflammation. Increasing the dose of methotrexate to 14 mg/m^2/week and ibuprofen to 20 mg/kg resolved her pain, but her movement was limited to walking with assistance. High dose methotrexate for a year did not decrease the limitation of her ankle joints; thus, tocilizumab was added to the methotrexate. After the tocilizumab (8 mg/kg/dose) was initiated, the joint limitation were resolved without any side effects, and the level of MMP-3 decreased by 53.7 ng/mL. However, she occasionally had pain in her wrists and right ankle; the ultrasound examination showed increased blood flow to the lunate bone and that the synovium of the right lateral malleolus had thinned. After 14 months of treatment with tocilizumab and one week of wash-out, the treatment was changed to adalimumab 40 mg (1.1 mg/kg/dose) every 2 weeks; she was free of any pain, stiffness, or recurrence just 2 months after its introduction. The level of MMP-3 decreased by 39.0 ng/mL, and the ultrasound examination showed no thickened synovium or increased blood flow. This patient had also been treated for NS. Immunosuppressant treatment can potentially improve the pain in inflammatory arthropathies; however, she developed joint pain when the immunosuppressant was slowly tapered. Some studies have reported an association between chromosome 18 and immunocompetence; haplo-insufficiency of the 18q22.3-q23 gene region might cause the immunoglobulin A deficiency phenotype (2), and chromosome 18 has a locus that is responsible for the regulation of both Th1 and Th2 cytokine production (3). Moreover, single nucleotide polymorphisms have been

Table I. Clinical and genetic profiles, and treatments for reported patients with abnormal chromosome 18 and chronic arthritis.

<table>
<thead>
<tr>
<th>Case</th>
<th>Age/sex</th>
<th>Breakpoint</th>
<th>Arthritis type</th>
<th>Treatment</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petty 1987</td>
<td>11 years</td>
<td>boy</td>
<td>Ring18</td>
<td>Aspirin Physical therapy</td>
<td>Complete response</td>
</tr>
<tr>
<td>Petty 1987</td>
<td>5.5 years</td>
<td>girl</td>
<td>Del (18) (q21.2-22)</td>
<td>Oligoarticular</td>
<td>Complete response</td>
</tr>
<tr>
<td>Fujii 1988</td>
<td>13 years</td>
<td>girl</td>
<td>Del (18) (q22-qter)</td>
<td>Polyarticular</td>
<td>Complete response</td>
</tr>
<tr>
<td>Hansen 1994</td>
<td>4 years</td>
<td>boy</td>
<td>Del (18) (q22-qter)</td>
<td>Oligoarticular</td>
<td>Partial response</td>
</tr>
<tr>
<td>Rosen 2004</td>
<td>8 years</td>
<td>girl</td>
<td>Del (18) (q22-qter)</td>
<td>Oligoarticular</td>
<td>Complete response</td>
</tr>
<tr>
<td>Salavoura 2007</td>
<td>5 years</td>
<td>girl</td>
<td>Telomere del 18q</td>
<td>Polyarticular</td>
<td>Unknown</td>
</tr>
<tr>
<td>Sali 2012</td>
<td>7 years</td>
<td>girl</td>
<td>Del (18) (q22-qter)</td>
<td>Polyarticular</td>
<td>Complete response</td>
</tr>
<tr>
<td>Current</td>
<td>11 years</td>
<td>girl</td>
<td>Del (18) (q22-qter)</td>
<td>Polyarticular</td>
<td>Complete response</td>
</tr>
</tbody>
</table>

Del: deletion; p and q: short and long chromosome arms; ter: terminal.

130
associated with rheumatoid arthritis (4). Up to now, 7 patients with chromosome 18 abnormalities and chronic arthritis have been reported (5-10); the current patient was the eighth case (Table I). Although the arthritis in these patients might be juvenile idiopathic arthritis (JIA), it was not possible to discern whether the arthritis was secondary to the chromosome abnormality or the co-occurrence of JIA and the manifestations of the 18q abnormalities. The arthritis conditions in these patients were not considered to be JIA but chronic arthritis, because the latter could not be excluded. A meta-analysis of a genome scan revealed that 18q21 was associated with rheumatoid arthritis (4), whereas the breaking point of the chromosome in 5 of 7 patients was 18q22. Arthritis may be caused by points which have not been revealed. In this patient’s case, high-dose methotrexate (14 mg/m²/week) failed to cure joint pain, whereas tocilizumab and adalimumab were successful in eliminating pain, resolving the limited joint mobility, and preventing the progression of bone destruction without adverse effects such as severe infection, myocardial damage, or dyslipidemia. The current case demonstrated that biological treatment can be effective for chronic arthritis in a patient with 18q-syndrome. Our case may also support the association between chromosome 18 and chronic arthritis.

Acknowledgements
We would like to thank Maya Takahashi, MD, Osamu Takeda, MD, Noriko Yoneyama, MD, and Wako Ishida, MD for valuable suggestions and interesting discussion concerning this case.

S. KASHIMA¹, MD
S. TSUCHIDA¹, MD
H. KOIZUMI¹, MD
¹Department of Paediatrics, Akita City Hospital, Japan, Akita City, Akita, Japan;
²Department of Paediatrics, Akita University School of Medicine, Akita City, Akita, Japan.
Address correspondence to:
Hiromi Koizumi, MD,
4-30 Kawamoto-Matsuoka-cho, Akita City, Akita, 010-0933, Japan.
E-mail: ac930946@akita-city-hp.jp
Reprint requests from: Soki Kashima, MD,
4-30 Kawamoto-Matsuoka-cho, Akita City, Akita, 010-0933, Japan.
E-mail: s4005534@gmail.com
Competing interests: none declared.

References